

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
09/114,810	07/13/1998	ANTHONY ATALA	CME-117	9691
21125	7590 08/16/2004		EXAM	INER
NUTTER MCCLENNEN & FISH LLP WORLD TRADE CENTER WEST			RODRIGUEZ, CRIS LOIREN	
	T BOULEVARD		ART UNIT	PAPER NUMBER
BOSTON, M	IA 02210-2604		3763	

DATE MAILED: 08/16/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)			
	09/114,810	ATALA ET AL.			
Office Action Summary	Examiner	Art Unit			
	Cris L. Rodriguez	3763			
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address			
A SHORTENED STATUTORY PERIOD FOR REPLY THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	36(a). In no event, however, may a reply be time within the statutory minimum of thirty (30) days will apply and will expire SIX (6) MONTHS from cause the application to become ABANDONED	nely filed s will be considered timely. the mailing date of this communication. O (35 U.S.C. § 133).			
Status					
1) Responsive to communication(s) filed on 01 Ju	<u>ıne 2004</u> .				
2a) This action is FINAL . 2b) ⊠ This					
Disposition of Claims	•				
4) ☐ Claim(s) 92-100 is/are pending in the application 4a) Of the above claim(s) is/are withdraw 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) 92-100 is/are rejected. 7) ☐ Claim(s) is/are objected to. 8) ☐ Claim(s) are subject to restriction and/or	vn from consideration.				
Application Papers		•			
9) The specification is objected to by the Examine	r.				
10)⊠ The drawing(s) filed on <u>01 June 2004</u> is/are: a)⊠ accepted or b)⊡ objected to by the Examiner.					
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).					
Replacement drawing sheet(s) including the correction 11) The oath or declaration is objected to by the Ex	,				
Priority under 35 U.S.C. § 119					
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority documents 2. Certified copies of the priority documents 3. Copies of the certified copies of the priority application from the International Bureau * See the attached detailed Office action for a list	s have been received. s have been received in Application ity documents have been receive I (PCT Rule 17.2(a)).	on No ed in this National Stage			
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal P				
Paper No(s)/Mail Date 6) Other:					

Application/Control Number: 09/114,810 Page 2

Art Unit: 3763

DETAILED ACTION

Claim Objections

1. Claim 100 is objected to under 37 CFR 1.75(c), as being of improper dependent form for failing to further limit the subject matter of a previous claim. Applicant is required to cancel the claim(s), or amend the claim(s) to place the claim(s) in proper dependent form, or rewrite the claim(s) in independent form. Claim 100 depends from itself.

Claim Rejections - 35 USC § 102

2. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

- (b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.
- (e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.
- 3. Claims 92-96, and 98 are rejected under 35 U.S.C. 102(b) as being anticipated by Barsotti et al (US 4,791,915).

Barsotti discloses a device 10 including an applicator 22, an ultrasound transducer including at least one oscillating element generating frequency between the range as claimed, a duty cycle greater than about 10%, a pressure switch in the control

Application/Control Number: 09/114,810 Page 3

Art Unit: 3763

unit 16, a controller for varying the frequency and power of the ultrasound energy, and a detector for monitoring feedback signals from the transducer.

4. Claims 92-98 are rejected under 35 U.S.C. 102(e) as being anticipated by Rowe et al (US 6,234,990).

Rowe discloses various therapeutic drug delivery devices (figs.1, 7-11) including an applicator, an ultrasound transducer including at least one oscillating element generating frequency between the range as claimed, a duty cycle greater than about 10%, a pressure switch (fig. 9), a compliant skin contacting material (Col. 11, lines 1-14), a controller for varying the frequency and power of the ultrasound energy, and a detector for monitoring feedback signals from the transducer. The device can deliver several kinds of drugs.

Claim Rejections - 35 USC § 112

- 5. The following is a quotation of the second paragraph of 35 U.S.C. 112:

 The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
- 6. Claim 99 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.
 - Claim 99, "the therapeutic agent" is not positively recited in the claims.

Claim Rejections - 35 USC § 103

- 7. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
 - (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and

Art Unit: 3763

the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

8. Claims 99 and 100 are rejected under 35 U.S.C. 103(a) as being unpatentable over Rowe et al in view of Neal (US 6,103,765).

Rowe discloses the invention substantially as claimed. Rowe's device can deliver several kinds of drugs. However, Rowe fails to disclose the drugs cited in claim 99, and more specifically a phosphodiesterase type-5 inhibitor such as sildenafil or alprostadil.

Neal teaches the use of sildenafil as a topical medicament for treating male erectile dysfunction. Given the teachings, it would have been obvious to one having ordinary skill in the art at the time the invention was made to use Neal's sildenafil with Rowe's device as an alternative way of topical drug delivery, since Rowe is capable of delivering other drugs.

Response to Arguments

9. Applicant's arguments with respect to the claims have been considered but are moot in view of the new ground(s) of rejection.

Conclusion

10. The prior art made of record and not relied upon is considered pertinent to applicant's disclosure. Eppstein et al, Kaufman et al, Kost et al, Elstrom et al, Lipkovker, Fox, and Abdelghani.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Cris L. Rodriguez whose telephone number is (703) 308-2194. The examiner can normally be reached on 7:30 am - 4:00 pm.

Application/Control Number: 09/114,810 Page 5

Art Unit: 3763

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Brian Casler can be reached on (703) 308-3552. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

August 13, 2004

Cris L. Rodriguez

Examiner Art Unit 3763